Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy / Resultados oncológicos en tumores testiculares no seminomatosos y masa residual posquimioterapia con cisplatino
urol. colomb. (Bogotá. En línea)
; 33(2): 55-60, 2024. tab, graf
Article
em En
| COLNAL, LILACS
| ID: biblio-1571251
Biblioteca responsável:
CO5.1
ABSTRACT
Objective:
The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and III NSGCT with an RM after primary or secondary CT with negative serum markers (NSM). A residual mass (RM) in non-seminomatous germ cell tumors (NSGCT) after chemotherapy (CT) is defined as a mass >1 cm in greatest diameter. The preferred treatment for RM is retroperitoneal lymph node dissection (RPLND), with a cure rate greater than 80%.Methods:
We identified 60 patients with NSGCT, RM, and NSM between 2007 and 2020. Data regarding clinical and oncological outcomes as well as pathological information were obtained in a retrospective fashion from our electronic database.Results:
A total of 60 patients were included. 50% of cases were CS II, and 50% CS III. About 90% of the patients had undergone RPLND. Teratoma was found in 73.6% of these patients. PFS and OS were better in CS II patients, compared to CS III. The patients treated with observation were found to have a shorter PFS compared to patients who underwent RPLND. Patients with viable tumors after RPLND had shorter OS compared to patients with teratoma and fibrosis.Conclusions:
RPLND continues to be the treatment of choice to patients with RM after CT and NSMRESUMEN
Objetivo:
Nuestro objetivo es describir la supervivencia libre de progresión (SLP) en pacientes con TCGNS en estadio clínico (CS) II y III con masa residual tras QT primaria o secundaria con marcadores séricos negativos (MSN).Métodos:
Se incluyeron pacientes con TCGNS, MR y MSN atendidos entre 2007-2020. Los datos se obtuvieron de forma retrospectiva de nuestra base de datos electrónica.Resultados:
Se identificaron 60 pacientes, el 50% eran CS II y el 50% CS III, y el 90% de los pacientes fueron sometidos a DGLRP. Se evidenció teratoma en el 73,6% de los pacientes. La SLP y la supervivencia global (SG) fue mejor en pacientes con CS II, frente a CS III. Los pacientes observados tuvieron una SLP menor frente a los que se sometieron a DGLRP. Los pacientes tratados con DGLRP y evidencia de tumor viable en la patología tenían una SG más corta comparado con teratomay fibrosis.Conclusión:
La DGLRP sigue siendo el tratamiento de elección para las MR posterior a QT y MSN.Assuntos
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
COLNAL
/
LILACS
Assunto principal:
Pacientes
/
Sobrevivência
Limite:
Humans
/
Male
Idioma:
En
Revista:
Urol. colomb. (Bogotá. En línea)
Assunto da revista:
Urologia
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Colômbia
País de publicação:
Colômbia